ArticleThe Journal of clinical endocrinology and metabolism2024

Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.

Jing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.